Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Liu, Xian Ping ^a   Zhou, Sheng Tao ^a   Li, Xing Yi ^b   Chen, Xian Cheng ^b   Zhao, Xia ^a   Qian, Zhi Yong ^b   Zhou, Li Na ^a   Li, Zhi Yong ^b   Wang, Yu Mei ^a   Zhong, Qian ^a   Yi, Tao ^a   Li, Zheng Yu ^a   He, Xiang ^a   Wei, Yu Quan ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHITOSAN DERIVATIVE; N TRIMETHYL CHITOSAN; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHITOSAN; DRUG CARRIER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NANOENCAPSULATION; NICK END LABELING; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRASOUND; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; EXPERIMENTAL MELANOMA; NUDE MOUSE; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHITOSAN; DRUG CARRIERS; FEMALE; IMMUNOENZYME TECHNIQUES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; SOLUBILITY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953546375     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-76     Document Type: Article

References (35)

1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. ME Wall MC Wani EC Cook KH Palmer AT McPhail GA Sim, J Am Chem Soc 1966 88 3888 3890 10.1021/ja00968a057
2. Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. LM Wang QY Li YG Zu YJ Fu LY Chen HY Lv LP Yao SG Jiang, Chem-Biol Interact 2008 176 165 172 10.1016/j.cbi.2008.07.005 18708040
3. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. AH Van Hattum HM Pinedo HM Schluper CA Erkelens A Tohgo E Boven, Biochem Pharmacol 2002 64 1267 1277 10.1016/S0006-2952(02)01297-2 12234607
4. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. V Knight MV Koshkina JC Waldrep BC Giovanella BE Gilbert, Cancer Chemoth Pharm 1999 44 177 86 10.1007/s002800050965 (Pubitemid 29350172)
5. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. DH Lee S-W Kim C Suh J-S Lee JH Lee S-J Lee BY Ryoo K Park JS Kim DS Heo NK Kim, Ann Oncol 2008 19 123 127 10.1093/annonc/mdm437 17823384
6. Efficacy of Camptothecin Analog DX-8951f (Exatecan Mesylate) on Human Pancreatic Cancer in an Orthotopic Metastatic Model. Fang-Xian Sun Akiko Tohgo Michael Bouvet Shigeo Yagi Rounak Nassirpour R Moossa Abdoul M Hoffman Robert, Cancer Res 2003 63 80 85 12517781
7. Enhancing the anticancer efficacy of camptothecin using biotinylated poly (ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. T Minko PV Paranjpe B Qiu A Lalloo R Won S Stein PJ Sinko, Cancer Chemoth Pharm 2002 50 143 50 10.1007/s00280-002-0463-1 (Pubitemid 34969511)
8. Preparation and Characterization of Collagen/Chitosan Matrices as Potential Biomaterials. XH Wang FZ Cui QL Feng JC Li YH Zhang, J Bioact Compat Pol 2003 18 453 467 10.1177/0883911503040434 (Pubitemid 38101525)
9. A Review of Chitin and Chitosan Applications. NV Majeti Ravi Kumar, React Funct Polym 2000 46 1 27 10.1016/S1381-5148(00)00038-9
10. Intestinal Absorption of Octreotide: N-Trimethyl Chitosan Chloride (TMC) Ameliorates the Permeability and Absorption Properties of the Somatostatin Analogue In Vitro and In Vivo. M Thanou JC Verhoef P Marbach HE Junginger, J Pharm Sci 2000 89 951 957 10.1002/1520-6017(200007)89:7<951::AID-JPS13>3. 0.CO;2-1 10861597
11. Early detection and treatment of skin cancer. AF Jerant JT Johnson CD Sheridan TJ Caffrey, Am Fam Physician 2000 62 357 68 375-6, 381-2 10929700
12. Melanoma genetics and therapeutic approaches in the21st century: moving from the benchside to the bedside. TL Hocker MK Singh H Tsao, J Invest Dermatol 2008 128 2575 95 10.1038/jid.2008.226 18927540
13. Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Q Li YQ Wei YJ Wen X Zhao L Tian L Yang YQ Mao B Kan Y Wu ZY Ding HX Deng J Li Y Luo HL Li QM He JM Su F Xiao CH Zou CH Fu XJ Xie T Yi GH Tan L Wang J Chen J Liu ZN Gao, Int J Cancer 2004 112 143 9 10.1002/ijc.20276 15305386
14. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. LP Yang P Cheng XC Peng HS Shi WH He FY Cui ST Luo YQ Wei L Yang, J Exp Clin Canc Res 2009 28 75 10.1186/1756-9966-28-75
15. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Weidner JP Semple WR Welch J Folkman, New Engl J Med 1991 324 1 8 1701519
16. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34 - Ala mutant. XC Peng L Yang LP Yang YQ Mao HS Yang JY Liu DM Zhang LJ Chen YQ Wei, J Exp Clin Canc Res 2008 27 46 10.1186/1756-9966-27-46
17. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. J Panyam V Labhasetwar, Adv Drug Deliver Rev 2003 55 329 47 10.1016/S0169-409X(02)00228-4 (Pubitemid 36297053)
18. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. A Enriquez de Salamanca Y Diebold M Calonge C Garcia-Vazquez S Callejo A Vila MJ Alonso, Invest Ophth Vis Sci 2006 47 1416 25 10.1167/iovs.05-0495 (Pubitemid 46780748)
19. Intestinal paracellular permeation enhancement with quaternised chitosan: in situ and in vitro evaluation. C Jonker JH Hamman AF Kotze, Int J Pharm 2002 238 205 213 10.1016/S0378-5173(02)00068-6 11996824
20. Synthesis and characterization of sugar-bearing chitosan derivatives: aqueous solubility and biodegradabi1ity. JH Park YW Cho H Chung IC Kwon SY Jeong, Biomacromolecules 2003 4 1087 91 10.1021/bm034094r 12857096
21. Novel N-saturated-fatty-acyl derivatives of chitosan soluble in water and in aqueous acid and alkaline solutions. S Hirano Y Yamaguchi M Kamiya, Carbohyd Polym 2002 48 203 207 10.1016/S0144-8617(01)00243-0 (Pubitemid 34070326)
22. Preparation and antibacterial activity of a water-soluble chitosan derivative. W Xie P Xu W Wang Q Liu, Carbohyd Polym 2002 50 35 40 10.1016/S0144-8617(01)00370-8 (Pubitemid 34614114)
23. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. TG Burke Z Mi, J Med Chem 1994 37 40 6 10.1021/jm00027a005 8289200
24. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. F Cengelli JA Grzyb A Montoro H Hofmann S Hanessian L Juillerat-Jeanneret, ChemMedChem 2009 4 988 97 10.1002/cmdc.200800424 19347834
25. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. ZR Huang SC Hua YL Yang JY Fang, Acta Pharmacol Sin 2008 29 1094 102 10.1111/j.1745-7254.2008.00829.x 18718178
26. Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. G Loch-Neckel D Nemen AC Puhl D Fernandes MA Stimamiglio M Alvarez Silva M Hangai MC Santos Silva E Lemos-Senna, J Pharm Pharmacol 2007 59 1359 64 10.1211/jpp.59.10.0005 17910810
27. Transport of molecules in the tumor interstitium: A review. RK Jain, Cancer Res 1987 47 3039 3051 3555767
28. Control of tumor vascular permeability. D Baban LW Seymour, Adv Drug Deliver Rev 1998 34 109 119 10.1016/S0169-409X(98)00003-9 (Pubitemid 28464481)
29. What is the evidence that tumors are angiogenesis dependent? J Folkman, J Natl Cancer I 1990 82 4 6 10.1093/jnci/82.1.4
30. Tumor angiogenesis: therapeutic implications. J Folkman, New Engl J Med 1971 285 1182 6 4938153
31. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. D Hanahan J Folkman, Cell 1996 86 353 64 10.1016/S0092-8674(00) 80108-7 8756718
32. Angiogenesis in cancer, vascular, rheumatoid and other disease. J Folkman, Nat Med 1995 1 27 31 10.1038/nm0195-27 7584949
33. Mechanisms of angiogenesis. W Risau, Nature 1997 386 671 4 10.1038/386671a0 9109485
34. Molecular mechanisms of blood vessel formation. F Bussolino A Mantovani G Persico, Trends Biochem Sci 1997 22 251 6 10.1016/S0968-0004(97)01074-8 9255066
35. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. J Dixelius H Larsson T Sasaki K Holmqvist L Lu A Engstrom R Timpl M Welsh L Claesson-Welsh, Blood 2000 95 3403 11 10828022